$131 Million is the total value of Asymmetry Capital Management, L.P.'s 32 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 155.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMYRT | Buy | BRISTOL-MYERS SQUIBB-CVRrts | $12,738,000 | +40.6% | 3,558,046 | +49.2% | 9.76% | -1.5% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $10,815,000 | +144.5% | 171,316 | +97.9% | 8.29% | +71.3% |
| SAGE | New | SAGE THERAPEUTICS INC | $8,202,000 | – | 197,249 | +100.0% | 6.28% | – |
| GH | Buy | GUARDANT HEALTH INC | $7,792,000 | +46.5% | 96,039 | +25.6% | 5.97% | +2.6% |
| ASND | Buy | ASCENDIS PHARMA A/S - ADRadr | $7,040,000 | +122.0% | 47,599 | +69.0% | 5.39% | +55.5% |
| NSTG | Buy | NANOSTRING TECHNOLOGIES INC | $6,445,000 | +259.7% | 219,577 | +194.7% | 4.94% | +151.9% |
| MNTA | Buy | MOMENTA PHARMACEUTICALS INC | $5,296,000 | +134.3% | 159,197 | +91.6% | 4.06% | +64.2% |
| CNC | Buy | CENTENE CORP | $4,919,000 | +407.6% | 77,402 | +374.3% | 3.77% | +255.6% |
| CYTK | Buy | CYTOKINETICS INC | $4,857,000 | +101.7% | 206,086 | +0.9% | 3.72% | +41.3% |
| TXG | Buy | 10X GENOMICS INC-CLASS A | $4,539,000 | +196.1% | 50,819 | +106.6% | 3.48% | +107.4% |
| AVDL | New | AVADEL PHARMACEUTICALS PLCadr | $4,312,000 | – | 533,632 | +100.0% | 3.30% | – |
| ATRS | New | ANTARES PHARMA INC | $3,573,000 | – | 1,299,202 | +100.0% | 2.74% | – |
| BNTX | New | BIONTECH SEadr | $2,578,000 | – | 38,626 | +100.0% | 1.98% | – |
| LPTX | New | LEAP THERAPEUTICS INC | $1,883,000 | – | 900,733 | +100.0% | 1.44% | – |
| AIMT | New | AIMMUNE THERAPEUTICS INC | $1,680,000 | – | 100,544 | +100.0% | 1.29% | – |
| MGTA | New | MAGENTA THERAPEUTICS INC | $1,585,000 | – | 211,063 | +100.0% | 1.21% | – |
| BLUE | New | BLUEBIRD BIO INC | $1,526,000 | – | 25,000 | +100.0% | 1.17% | – |
| GRTS | New | GRITSTONE ONCOLOGY INC | $1,480,000 | – | 222,817 | +100.0% | 1.13% | – |
| TPTX | New | TURNING POINT THERAPEUTICS I | $1,460,000 | – | 22,608 | +100.0% | 1.12% | – |
| RCUS | New | ARCUS BIOSCIENCES INC | $1,264,000 | – | 51,074 | +100.0% | 0.97% | – |
| UBX | New | UNITY BIOTECHNOLOGY INC | $1,043,000 | – | 120,179 | +100.0% | 0.80% | – |
| NXTC | New | NEXTCURE INC | $1,039,000 | – | 48,456 | +100.0% | 0.80% | – |
| RAPT | New | RAPT THERAPEUTICS INC | $1,006,000 | – | 34,652 | +100.0% | 0.77% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.